# R3HDM1

## Overview
R3HDM1 is a gene that encodes the R3H domain-containing 1 protein, which is characterized by its involvement in RNA binding and cellular interactions. The protein features an R3H domain, known for its polynucleotide binding capabilities, and a SUZ domain, which facilitates RNA binding and localization within the cell (Fukushi2021R3HDM1; Itisam2024The). R3HDM1 is implicated in various cellular processes, including dendritic growth and branching, and plays a significant role in cancer progression and immune response modulation (Fukushi2021R3HDM1; Liu2024Comprehensive). The gene's expression and mutations are associated with clinical conditions such as cancer and intellectual disabilities, highlighting its importance in both oncological and neurodevelopmental contexts (Fukushi2021R3HDM1; Liu2024Comprehensive).

## Structure
The R3HDM1 protein is composed of 1100 amino acids and features two key domains: the R3H domain and the SUZ domain. The R3H domain is responsible for polynucleotide binding and is characterized by conserved arginine (R) and histidine (H) residues separated by three amino acids, forming a single-stranded nucleic acid binding motif (Fukushi2021R3HDM1; Itisam2024The). The SUZ domain, composed of positively charged amino acids, mediates RNA binding and is associated with protein localization to specific sub-cellular structures (Itisam2024The).

R3HDM1 shares about 50% identical amino acids and 67% homology with the TARPP protein, indicating a significant degree of structural similarity (Itisam2024The). The protein is involved in RNA binding and is suggested to play a role in dendritic growth and branching, as evidenced by knockdown experiments in mouse neurons (Fukushi2021R3HDM1).

The molecular structure of R3HDM1 beyond these domains is not detailed in the available literature, and specific information on its secondary, tertiary, and quaternary structures, as well as post-translational modifications or splice variant isoforms, is not provided in the context.

## Clinical Significance
The R3HDM1 gene has been implicated in various diseases and conditions due to mutations and alterations in its expression. In cancer, R3HDM1 is identified as a predictive biomarker for prognosis and immune therapy response. Its high expression is associated with poor prognosis in several cancers, including lung adenocarcinoma (LUAD), and is linked to tumor progression and metastasis (Liu2024Comprehensive). The gene's expression is correlated with immune evasion and an immunosuppressive tumor environment, suggesting its role in immune-tumor interactions (Liu2024Comprehensive). R3HDM1 mutations have been identified as potential drivers of tumorigenesis in microsatellite-instable colorectal cancers (Tuupanen2014Identification).

In the context of intellectual disability, R3HDM1 haploinsufficiency has been associated with mild intellectual disability (ID) and developmental delay. A study reported a case of a 12-year-old boy with mild ID linked to a de novo pericentric inversion affecting R3HDM1, suggesting that haploinsufficiency of this gene may contribute to the condition (Fukushi2021R3HDM1). Knockdown experiments in mouse neurons showed that reduced R3HDM1 expression suppressed dendritic growth and branching, indicating its role in neuronal development (Fukushi2021R3HDM1). These findings highlight the clinical significance of R3HDM1 in both cancer and neurodevelopmental disorders.

## Interactions
R3HDM1, an RNA-binding protein with an R3H domain, is involved in various interactions with other proteins and cellular pathways. It interacts with functional proteins such as TFRC, MTOR_pS2448, and X4EBP1, which are crucial in metabolism, apoptosis, signaling, cell cycle regulation, and proliferation (Liu2024Comprehensive). These interactions suggest that R3HDM1 plays a significant role in cellular processes related to cancer progression and response to therapy.

The study by Liu et al. highlights R3HDM1's involvement in the tumor microenvironment and its association with immune cell infiltration. R3HDM1 expression is positively correlated with immune cells, including B cells, CD4+ T cells, CD8+ T cells, and Treg cells, indicating its role in immune evasion and modulation of the immune microenvironment (Liu2024Comprehensive). This interaction with immune cells suggests that R3HDM1 may influence immune responses in cancer.

In addition to protein interactions, R3HDM1 is implicated in the regulation of nucleic acids. The R3H domain is known for binding single-stranded nucleic acids, which suggests potential roles in RNA processing or regulation, although specific nucleic acid interactions are not detailed in the provided context. Overall, R3HDM1's interactions with proteins and potential nucleic acid binding highlight its multifaceted role in cellular and molecular processes.


## References


[1. (Fukushi2021R3HDM1) Daisuke Fukushi, Mie Inaba, Kimiko Katoh, Yasuyo Suzuki, Yasushi Enokido, Noriko Nomura, Yoshihito Tokita, Shin Hayashi, Seiji Mizuno, Kenichiro Yamada, and Nobuaki Wakamatsu. <scp>r3hdm1</scp> haploinsufficiency is associated with mild intellectual disability. American Journal of Medical Genetics Part A, 185(6):1776–1786, March 2021. URL: http://dx.doi.org/10.1002/ajmg.a.62173, doi:10.1002/ajmg.a.62173. This article has 1 citations.](https://doi.org/10.1002/ajmg.a.62173)

2. (Itisam2024The) The role of previously uncharacterized RNA binding proteins in hematopoiesis. This article has 0 citations.

[3. (Liu2024Comprehensive) Jiawei Liu, Zhitong Bing, and Junling Wang. Comprehensive pan-cancer analysis and experiments revealed r3hdm1 as a novel predictive biomarker for prognosis and immune therapy response. Frontiers in Genetics, September 2024. URL: http://dx.doi.org/10.3389/fgene.2024.1404348, doi:10.3389/fgene.2024.1404348. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2024.1404348)

[4. (Tuupanen2014Identification) S Tuupanen, U A Hänninen, J Kondelin, P von Nandelstadh, T Cajuso, A E Gylfe, R Katainen, T Tanskanen, H Ristolainen, J Böhm, J-P Mecklin, H Järvinen, L Renkonen-Sinisalo, C L Andersen, M Taipale, J Taipale, P Vahteristo, K Lehti, E Pitkänen, and L A Aaltonen. Identification of 33 candidate oncogenes by screening for base-specific mutations. British Journal of Cancer, 111(8):1657–1662, August 2014. URL: http://dx.doi.org/10.1038/bjc.2014.429, doi:10.1038/bjc.2014.429. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.2014.429)